DOCSLIB.ORG

Api Extract of Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Api Extract of Product List 1 API EXTRACT OF PRODUCT LIST Active pharmaceutical ingredient Documentation Abacavir Hemisulphate PIC/S member GMP or COFEPRIS GM Acarbose PIC/S member GMP or COFEPRIS GM Aceclofenac EP/BP PIC/S member GMP or COFEPRIS GM Acefylline Piperazine PIC/S member GMP or COFEPRIS GM Acemetacin PIC/S member GMP or COFEPRIS GM Acenocumarol EP PIC/S member GMP or COFEPRIS GM Acepifylline PIC/S member GMP or COFEPRIS GM Acetanilide PIC/S member GMP or COFEPRIS GM Acetazolamide USP PIC/S member GMP or COFEPRIS GM Acetonide PIC/S member GMP or COFEPRIS GM Acetyl L-Carnitine Hydrochloride PIC/S member GMP or COFEPRIS GM Aciclovir IP/BP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Aciclovir Sodium PIC/S member GMP or COFEPRIS GM Aciclovir USP PIC/S member GMP or COFEPRIS GM Adapalene PIC/S member GMP or COFEPRIS GM Adefovir Dipivoxil PIC/S member GMP or COFEPRIS GM Adenosine PIC/S member GMP or COFEPRIS GM Albendazole USP PIC/S member GMP or COFEPRIS GM Albuterol Sulphate USP PIC/S member GMP or COFEPRIS GM Alclometasone PIC/S member GMP or COFEPRIS GM Alendronate Sodium Trihydrate PIC/S member GMP or COFEPRIS GM Alendronate Sodium USP/BP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Alfacalcidol PIC/S member GMP or COFEPRIS GM Alfuzosin Hydrochloride BP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Algamon PIC/S member GMP or COFEPRIS GM Allopurinol PIC/S member GMP or COFEPRIS GM alpha-Hydroxyprogesterone PIC/S member GMP or COFEPRIS GM Alprazolam IP/BP/EP/USP PIC/S member GMP or COFEPRIS GM Alprostadil PIC/S member GMP or COFEPRIS GM Altrenogest PIC/S member GMP or COFEPRIS GM Aluminium Chloride 25% PIC/S member GMP or COFEPRIS GM Ambazone PIC/S member GMP or COFEPRIS GM Ambroxol PIC/S member GMP or COFEPRIS GM Amiloride Chlorhydrate Dihydrate PIC/S member GMP or COFEPRIS GM Aminophyllin Hydrous PIC/S member GMP or COFEPRIS GM Aminophylline Anhydrous PIC/S member GMP or COFEPRIS GM Aminotridecane Adipate PIC/S member GMP or COFEPRIS GM Amiodarone Hydrochloride IP/BP/USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Amisulpride USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Amitriptyline Hydrochloride PIC/S member GMP or COFEPRIS GM Amitriptyline Hydrochloride BP/JP/USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Amlodipine Besilate PIC/S member GMP or COFEPRIS GM Amlodipine Besilate EP PIC/S member GMP or COFEPRIS GM Amlodipine Besilate Ph.Eur./EP PIC/S member GMP or COFEPRIS GM M.P.I. Pharmaceutica GmbH . An der Alster 47 . 20099 Hamburg . Germany . T: +49 (40) 30 37 24-0 . F: +49 (40) 30 37 24-20 2 API EXTRACT OF PRODUCT LIST Active pharmaceutical ingredient Documentation Amlodipine Maleate PIC/S member GMP or COFEPRIS GM Amlodipine Mesylate PIC/S member GMP or COFEPRIS GM Amobarbital Sodium PIC/S member GMP or COFEPRIS GM Amodiaquine Base PIC/S member GMP or COFEPRIS GM Amodiaquine Hydrochloride PIC/S member GMP or COFEPRIS GM Amoxicillin Sodium (Sterile) PIC/S member GMP or COFEPRIS GM Ampicillin Sodium (Sterile) PIC/S member GMP or COFEPRIS GM Amtolmetin Guacil PIC/S member GMP or COFEPRIS GM Amylmetacresol PIC/S member GMP or COFEPRIS GM Anagrelide Hydrochloride PIC/S member GMP or COFEPRIS GM Anastrozole PIC/S member GMP or COFEPRIS GM Antazoline Phosphate PIC/S member GMP or COFEPRIS GM Aprepitant PIC/S member GMP or COFEPRIS GM Arginine (Sterile) PIC/S member GMP or COFEPRIS GM Aripiprazole PIC/S member GMP or COFEPRIS GM Artemether PIC/S member GMP or COFEPRIS GM Artesunate PIC/S member GMP or COFEPRIS GM Ascorbic Acid PIC/S member GMP or COFEPRIS GM Atazanavir PIC/S member GMP or COFEPRIS GM Atenolol EP/USP PIC/S member GMP or COFEPRIS GM Atomoxetine Hydrochloride PIC/S member GMP or COFEPRIS GM Atorvastatin Calcium IHS/IP PIC/S member GMP or COFEPRIS GM Atorvastatin Crystalline PIC/S member GMP or COFEPRIS GM Avizafone PIC/S member GMP or COFEPRIS GM Azathioprine BP/USP PIC/S member GMP or COFEPRIS GM Azelastine Hydrochloride PIC/S member GMP or COFEPRIS GM Azithromycin BP/EP/USP PIC/S member GMP or COFEPRIS GM Azithromycin Dihydrate USP32 PIC/S member GMP or COFEPRIS GM Azithromycin IP/BP/USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Azithromycin USP PIC/S member GMP or COFEPRIS GM Bacitracin Zinc PIC/S member GMP or COFEPRIS GM Baclofen PIC/S member GMP or COFEPRIS GM Balsalazide PIC/S member GMP or COFEPRIS GM Bamifylline Chlorhydrate PIC/S member GMP or COFEPRIS GM Barbexaclone PIC/S member GMP or COFEPRIS GM Beclomethasone Dipropionate PIC/S member GMP or COFEPRIS GM Benazepril PIC/S member GMP or COFEPRIS GM Benazepril Hydrochloride IHS PIC/S member GMP or COFEPRIS GM Benazepril Hydrochloride USP PIC/S member GMP or COFEPRIS GM Bendroflumethiazide PIC/S member GMP or COFEPRIS GM Benzocaine BP/USP PIC/S member GMP or COFEPRIS GM Benzoyl Metronidazole BP PIC/S member GMP or COFEPRIS GM Benzydamine Hydrochloride BP PIC/S member GMP or COFEPRIS GM Benzyl Pethidine Base PIC/S member GMP or COFEPRIS GM M.P.I. Pharmaceutica GmbH . An der Alster 47 . 20099 Hamburg . Germany . T: +49 (40) 30 37 24-0 . F: +49 (40) 30 37 24-20 3 API EXTRACT OF PRODUCT LIST Active pharmaceutical ingredient Documentation Benzylpenicillin Procaine PIC/S member GMP or COFEPRIS GM Benzylpenicillin Procaine 3:1 (Sterile) BP PIC/S member GMP or COFEPRIS GM Betahistine PIC/S member GMP or COFEPRIS GM Betahistine Dichlorhydrate (incl. Impurity Kit and WS) PIC/S member GMP or COFEPRIS GM Betahistine Hydrochloride PIC/S member GMP or COFEPRIS GM Betahistine Mesylate PIC/S member GMP or COFEPRIS GM Betamethasone 17-Valerate PIC/S member GMP or COFEPRIS GM Betamethasone Acetate PIC/S member GMP or COFEPRIS GM Betamethasone Base PIC/S member GMP or COFEPRIS GM Betamethasone Benzoate PIC/S member GMP or COFEPRIS GM Betamethasone Butyrate PIC/S member GMP or COFEPRIS GM Betamethasone Dipropionate PIC/S member GMP or COFEPRIS GM Betamethasone Dipropionate BP2009/USP32 PIC/S member GMP or COFEPRIS GM Betamethasone Dipropionate Micronized (Sterile) USP34 PIC/S member GMP or COFEPRIS GM Betamethasone Phosphate PIC/S member GMP or COFEPRIS GM Betamethasone Sodium Phosphate (Sterile) PIC/S member GMP or COFEPRIS GM Betamethasone Sodium Phosphate USP34 PIC/S member GMP or COFEPRIS GM Betamethasone Valerate PIC/S member GMP or COFEPRIS GM Betamethasone Valerate Acetate PIC/S member GMP or COFEPRIS GM Betaxolol Chlorhydrate PIC/S member GMP or COFEPRIS GM Betaxolol Hydrochloride PIC/S member GMP or COFEPRIS GM Bicalutamide PIC/S member GMP or COFEPRIS GM Bicalutamide USP PIC/S member GMP or COFEPRIS GM Bicarbonate Buffer (Sterile) PIC/S member GMP or COFEPRIS GM Bifendate PIC/S member GMP or COFEPRIS GM Biperiden Hydrochloride and Base PIC/S member GMP or COFEPRIS GM Bisacodyl BP/EP/USP PIC/S member GMP or COFEPRIS GM Bisacodyl BP/USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Bisacodyl IP PIC/S member GMP or COFEPRIS GM Bisoprolol Fumarate USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Bosentan Monohydrate PIC/S member GMP or COFEPRIS GM Brimonidine Tartrate (In-House) PIC/S member GMP or COFEPRIS GM Brinzolamide PIC/S member GMP or COFEPRIS GM Brivudine PIC/S member GMP or COFEPRIS GM Bromazepam BP/EP PIC/S member GMP or COFEPRIS GM Bromfenac Sodium PIC/S member GMP or COFEPRIS GM Bromopride PIC/S member GMP or COFEPRIS GM Budesonide Micronized (Sterile) PIC/S member GMP or COFEPRIS GM Budesonide USP/BP PIC/S member GMP or COFEPRIS GM Bumadizone Calcium Hemihydrate PIC/S member GMP or COFEPRIS GM Bupivacaine Hydrochloride BP/USP/Ph.Eur. PIC/S member GMP or COFEPRIS GM Buprenorphine Base PIC/S member GMP or COFEPRIS GM Buprenorphine Hydrochloride PIC/S member GMP or COFEPRIS GM Bupropion Hydrochloride IHS/USP PIC/S member GMP or COFEPRIS GM M.P.I. Pharmaceutica GmbH . An der Alster 47 . 20099 Hamburg . Germany . T: +49 (40) 30 37 24-0 . F: +49 (40) 30 37 24-20 4 API EXTRACT OF PRODUCT LIST Active pharmaceutical ingredient Documentation Buserelin EP PIC/S member GMP or COFEPRIS GM Cabergoline EP PIC/S member GMP or COFEPRIS GM Caffeine Anhydrous PIC/S member GMP or COFEPRIS GM Calcifediol Monohydrate PIC/S member GMP or COFEPRIS GM Calcipotriol Anhydrous PIC/S member GMP or COFEPRIS GM Calcitonin EP/BP PIC/S member GMP or COFEPRIS GM Calcitriol PIC/S member GMP or COFEPRIS GM Calcium Acetate PIC/S member GMP or COFEPRIS GM Calcium and Magnesium Gluconolactate PIC/S member GMP or COFEPRIS GM Calcium Citrate Malate (DC Grade 94%) PIC/S member GMP or COFEPRIS GM Calcium Citrate USP PIC/S member GMP or COFEPRIS GM Calcium Gluconate IP PIC/S member GMP or COFEPRIS GM Calcium Gluconolactate PIC/S member GMP or COFEPRIS GM Calcium Hydrogen Phosphate PIC/S member GMP or COFEPRIS GM Calcium Pidolate PIC/S member GMP or COFEPRIS GM Camptothecin PIC/S member GMP or COFEPRIS GM Candesartan Cilexetil PIC/S member GMP or COFEPRIS GM Capecitabine USP PIC/S member GMP or COFEPRIS GM Carbachol PIC/S member GMP or COFEPRIS GM Carbamazepine IP/BP/USP/EP PIC/S member GMP or COFEPRIS GM Carbamazepine Micronized IP/BP PIC/S member GMP or COFEPRIS GM Carbetocin PIC/S member GMP or COFEPRIS GM Carbidopa IP PIC/S member GMP or COFEPRIS GM Carbonate (Sterile) PIC/S member GMP or COFEPRIS GM Carboplatin USP PIC/S member GMP or COFEPRIS GM Carteolol Chlorhydrate PIC/S member GMP or COFEPRIS GM Carvedilol PIC/S member GMP or COFEPRIS GM Carvedilol Ph.Eur.
Load more

Recommended publications
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Effect of Early Vasopressin Vs Norepinephrine On
    Protocol Number: CRO1888 VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic Shock PROTOCOL NUMBER: CRO1888 EudraCT NUMBER: 2011-005363-24 SPONSOR: Imperial College London FUNDER: National Institute for Health Research DEVELOPMENT PHASE: PHASE IV STUDY COORDINATION CENTRE: Imperial Clinical Trials Unit PROTOCOL Version & Date: Version 2.1, 02.08.2013 Property of: Dr Anthony Gordon May not be used, divulged or published without the consent of: Dr Anthony Gordon Confidential Final Version2.1, 02.08.2013 Page 1 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 Study Management Group Chief Investigator: Dr Anthony Gordon Co-investigators: Dr Stephen Brett Prof Gavin Perkins Prof Deborah Ashby Statistician: Dr Alexina Mason Trial Management: Ms Neeraja Thirunavukkarasu Study Coordination Centre For general queries, supply of trial documentation, and collection of data, please contact: Study Coordinator: Ms Neeraja Thirunavukkarasu Address: ICU – 11N, Charing Cross Hospital, Fulham Palace Road London W6 8RF E-mail: [email protected] Clinical Queries Clinical queries should be directed to Ms Neeraja Thirunavukkarasu who will direct the query to the appropriate person Sponsor Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at: Joint Research Compliance Office 510, Lab block, 5th Floor Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 0203 311 0213 Fax: 0203 311 0203 Funder National Institute for Health Research – Research for Patient Benefit and Clinician Scientist award schemes This protocol describes the VANISH study and provides information about procedures for entering participants.
    [Show full text]
  • WO 2013/066179 Al 10 May 2013 (10.05.2013) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/066179 Al 10 May 2013 (10.05.2013) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/127 (2006.01) A61P 29/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/NL20 12/050766 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 November 2012 (02.1 1.2012) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PCT/NL201 1/050755 (84) Designated States (unless otherwise indicated, for every 4 November 20 11 (04. 11.20 11) NL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: ENCELADUS PHARMACEUTICALS B.V.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (Anti-)Androgenic Activities in Aquatic Environments?
    Environmental Pollution 242 (2018) 417e425 Contents lists available at ScienceDirect Environmental Pollution journal homepage: www.elsevier.com/locate/envpol Do progestins contribute to (anti-)androgenic activities in aquatic environments?* * Pavel Sauer , Adam Borík, Oksana Golovko, Roman Grabic, Andrea Vojs Stanov a, Olga Valentova, Alzbeta Stara, Marie Sandova, Hana Kocour Kroupova University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Research Institute of Fish Culture and Hydrocenoses, Zati sí 728/II, 389 25 Vodnany, Czech Republic article info abstract Article history: Unknown compounds with (anti-)androgenic activities enter the aquatic environment via municipal Received 21 May 2018 wastewater treatment plants (WWTPs). Progestins are well-known environmental contaminants capable Received in revised form of interfering with androgen receptor (AR) signaling pathway. The aim of the present study was to 28 June 2018 determine if 15 selected progestins have potential to contribute to (anti-)androgenic activities in Accepted 30 June 2018 municipal wastewaters and the respective recipient surface waters. AR-specific Chemically Activated Available online 4 July 2018 LUciferase gene eXpression bioassay in agonistic (AR-CALUX) and antagonistic (anti-AR-CALUX) modes and liquid chromatography tandem atmospheric pressure chemical ionization/atmospheric photoioni- Keywords: Progestagens zation with hybrid quadrupole/orbital trap mass spectrometry operated in high resolution product scan Solid-phase extraction mode (LC-APCI/APPI-HRPS) methods were used to assess (anti-)androgenic activity and to detect the Target analysis target compounds, respectively. The contribution of progestins to (anti-)androgenic activities was Sample acidification evaluated by means of a biologically and chemically derived toxicity equivalent approach.
    [Show full text]
  • Regu-Mate® (Altrenogest) Management Practices and Potential for Exposure in Equine Care Givers
    Regu-Mate® (altrenogest) Management Practices and Potential for Exposure in Equine Care Givers A thesis submitted by Ariel Newman In partial fulfillment of the requirements for the degree of Master of Science in Civil and Environmental Engineering TUFTS UNIVERSITY August 2013 Advisers: Anne Marie C. Desmarais, Mark Woodin and Brett Gaby DVM ABSTRACT Regu-Mate, the synthetic progesterone altrenogest, is used to control estrus in horses. Equine caregivers handling Regu-Mate may be exposed through accidental exposure or inadequate safety procedures. This exposure can result in adverse health effects including menstrual cycle changes, uterine/abdominal cramping, headaches and prolonged pregnancy. Surveys asked equine caregivers about Regu-Mate handling procedures, skin exposure to the drug, symptoms associated with exposure to the drug, and general background information. I analyzed results through descriptive statistics. Most respondents do not take sufficient safety precautions when handling Regu-Mate. Respondents most commonly use rubber/latex gloves or do not wear gloves when handling the drug and/or use a non-locking syringe to withdraw the medication. Respondents become complacent, taking fewer precautions the longer and more often they handle Regu-Mate. I developed a risk communication program that outlines the important safe handling discussion topics between veterinarians and clients and recommends a periodic check- in to evaluate a facility’s procedures. ii ACKNOWLEDGMENTS I would like to express my sincerest gratitude to Anne Marie
    [Show full text]